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Abstract
Background:  Mycoplasma hominis is associated with pelvic inflammatory disease, bacterial
vaginosis, post partum fever, sepsis and infections of the central nervous system often leading to
serious conditions. Association with development of female infertility has also been suggested, but
different publications present different results. We developed a sensitive and fast diagnostic real-
time PCR to test clinical samples from women undergoing laparoscopic examination before fertility
treatment. To develop a test for the detection and quantification of M. hominis we selected a
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (gap), as a target.
Results: Real-time PCR was optimized to detect 10 copies of M. hominis PG21 genomic DNA. A
fluorescence signal was measured for all 20 other M. hominis isolates, and melting curves analysis
showed variations in the melting temperature in agreement with sequence variation in the region
of the probes. There was no amplification of other mycoplasmal DNA and human DNA. Eighty-
three patient cervical swab samples from infertile women were cultured for M. hominis in the BEa
medium. Two of the samples (2.4%) were positive after 48 hours of incubation. The real-time PCR
detected the same two samples positive, and the DNA concentrations in the clinical specimens
were calculated to 37.000 copies/ml and 88.500 copies/ml, respectively.
Conclusion: The results demonstrate that real-time PCR may prove to be a rapid alternative to
the traditional cultivation method. Information on bacterial load in genital swabs can be obtained.
The assay allowed detection of M. hominis in a closed system reducing the risk of contamination by
amplicon carry-over.
Background
Mycoplasmas are the smallest living prokaryotes known,
capable of self-replication. They belong to the class Molli-
cutes  and are distinguished phenotypically from other
bacteria by their minute size and lack of a cell wall. Genet-
ically they differ by having a small genome size and low
G+C content {1} [1]. Mycoplasmas have adapted to a
wide variety of hosts and can colonize man, other animals
and plants. The colonising organisms are host specific. In
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humans, mycoplasmas colonize mainly the upper respira-
tory tract and the genitourinary tract.
The first human Mycoplasma isolated was Mycoplasma hom-
inis  [2]. It is a heterogeneous genital mycoplasma [3]
found in at least two-thirds of women with bacterial vagi-
nosis (BV), compared to 10% of healthy women [4,5]. M.
hominis has also been isolated from the endometrium and
fallopian tubes of 10% women with salpingitis. However,
its role as a primary pathogen is doubtful since it co-exists
with many other bacteria in BV [6]. Studies made on
women undergoing in vitro fertilization showed the pres-
ence of M. hominis only in 2.1% of the women [7].
Isolation from other sites than the genitourinary tract has
been reported. M. hominis has been found to cause
wound, joint and central nervous system infections [8], it
has been isolated from cavernous angioma, but was not
the cause of the disease [9] and cases of brain and scalp
abscesses and meningoencephalitis were also reported
[10-15]. Those cases demonstrated the pathogenic poten-
tials of M. hominis and indicated a need for rapid recogni-
tion. So far culture is most commonly used for detection
of genital Mycoplasma, but it requires special handling,
complex media, and cultivation positive samples need
further testing to determinate the species cultivated [16].
A case report of brain abscess in a 22 year-old female
patient with postpartum infection [10] showed that cul-
ture took 4 – 5 days during which the patient's symptoms
continued to worsen before the antibiotic treatment was
changed.
Comparison between culture method and PCR has been
performed and showed that a PCR assay was as sensitive
as culture for detection of M. hominis from clinical sam-
ples. In addition it was very specific [17]. An advantage of
using PCR is that the system can detect the presence of
both live and dead microorganisms in the sample. When
comparing the original PCR protocols with the newly
developed real-time protocol, it offers interesting advan-
tages such as rapidity, closed system, which eliminates the
risk of carry-overs, real-time monitoring of PCR activity,
quantification of amplification product and, if required,
mutation analysis.
A recent study designed for the detection of M. hominis by
real-time PCR in HIV-positive patient swab samples, sug-
gested the use of SYBR Green with primers targeting
another housekeeping gene, the 16S rRNA gene [18]. The
16S rRNA gene is the most conserved microbial gene,
though, in M. hominis minor sequence variation was
observed [19]. Because sequences from M. hominis isolates
were available (see table 1 for accession nos.) and possible
to compare with other mycoplasmas sequence [28-30],
we selected the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (gap) as target for development
of a quantitative real-time PCR. Comparison of the DNA
sequences from different M. hominis isolates showed,
however, some small variations in the amplified DNA
sequence [31]. We determined sensitivity and specificity
of the M. hominis LightCycler real-time PCR and tested it
on clinical swab samples using specific hybridization
probes for detection.
Results
Design of primers and probes
The principles of the system we used are based on two spe-
cific hybridization probes located internally to the ampli-
fication primers, each of them labelled with a different
fluorescent dye [32]. The DNA sequence of primers and
probes is shown (table 2).
We selected M. hominis PG21 type strain as a template for
primers and probes. The primers and probes were
designed with respect to conservation of the DNA
sequence within the M. hominis gap gene [31] and differ-
ence from the related genital Mycoplasma genitalium gap
gene (Accession no. U39710) (fig. 1). The amplified DNA
fragment was of 144 bp in size.
Orientation of primers and probes with sequence compari- son to the closer related genital bacteria M. genitalium Figure 1
Orientation of primers and probes with sequence 
comparison to the closer related genital bacteria M. 
genitalium. The DNA sequence of primers and probes from 
M hominis PG21 is compared to the homologous M. genital-
ium sequence. Eight mismatches were present in the forward 
primer, 7 in the first probe, 15 in the second probe and 13 in 
the reverse primer I. Highlighted nucleotides correspond to 
mismatches. Letters in bold correspond to the beginnings 
and ends of designed primers (forward and reverse I) and 
probes (I, II). Letters in italic correspond to beginning and 
ending of reverse primer II. The active site region of GAPDH 
enzyme is underlined.
1. M. hominis PG21 
2.  M. genitalium    
                                  
   284                FORWARD PRIMER                  233 
PG21-gap  TTGAAGGAAC TGGAAGATAT GTAACAAAAG AAGGTGCTGA ATTACATATT 
  MG-gap  TTGAATCAAC TGGTAGGTTT GTAAGTGAAG AGGGTGCTTC TCTCCATTTA 
          234     I PROBE                383
                                         
PG21-gap  CAAGCAGGTG CTAAAAAGGT GTTTATTACT GCTCCAGCTA AAAGCGAAGG 
  MG-gap  AAAGCAGGTG CTAAAAGAGT AATTATTTCC GCACCCGCTA AAGAAAAAAC 
          384   II PROBE                   REVERSE PRIMER I  433 
PG21-gap  TGTTAAAACA GTTGTTTATT CAGTAAACGA AGATATCATT ACGCCAGAAG 
  MG-gap  TATCAGGACA GTTGTTTACA ATGTTAATCA CAAAACCATT AGTAGCGATG 
          434                                                483 
       REVERSE PRIMER II 
                 
PG21-gap  ATAAAATTTT ATCAGGCGCT TCATGTACTA CTAACTGTTT AGCTCCTATT 
  MG-gap  ATAAGATCAT CTCAGCAGCT AGCTGTACTA CTAACTGTTT AGCACCATTA BMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
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Swissprot Protein Database was used to determine the
amino acids sequence of GAPDH enzyme (E.C. no.
1.2.1.12). By use of the MOTIFS program the active site
was predicted to consist of the amino acids: ASCTTNCL,
located at nucleotides 451 to 474 (fig. 1) [31]. When com-
paring DNA sequences of the active site between M. hom-
inis and M. genitalium, only 3 out of 24 nucleotides are
mismatching (fig. 1), and therefore the probes and prim-
ers were placed before this region.
As seen from fig. 1, the G + C content of the M. hominis gap
gene is very low. It was difficult to find a suitable location
for the reverse primer, and therefore two reverse primers
were designed (table 2). The sequence of the reverse
primer II was partly overlapping the encoding region of
the active site of GAPDH enzyme. When compared it was
found that use of reverse primer I gave the highest sensi-
tivity of the LightCycler PCR assay. Concentration of 5
copies/µl of PG21 DNA was not always detected in PCR
runs when reverse primer II was used, whereas with use of
Table 1: List of the source of microbial and human DNA used in the assay
M. hominis isolates Isolation reference Isolation Source Accession no.gap gene
PG21 Nicol and Edward [20] Lower genitalia AJ243692
183 Linn and Kass [21] vagina
7357 Christiansen and Andersen [22] cervix AJ298001
6188 Christiansen and Andersen [22] cervix
3849 Christiansen and Andersen [22] cervix
P2 Thomsen [23] upper urinary system AJ298004
93 Linn and Kass [20] vagina AJ279227
4712 Christiansen and Andersen [22] cervix AJ297999
5941 Christiansen and Andersen [22] cervix AJ298000
DC63 Taylor-Robbinson [24] cavum oralis AJ298003
1893 Christiansen and Andersen [22] cervix
V2785 Taylor Robbinson [24] cavum oralis AJ298006
3105 Christiansen and Andersen [22] cervix AJ243694
W2 Lee [25] wound
P7 Thomsen [23] upper urinary system
SC4 Hollingdale and Lemcke [26] urethra, male AJ298005
132 Linn and Kass [21] vagina AJ243693
P71 Thomsen [23] upper urinary system
7808 Christiansen and Andersen [22] urethra, female AJ298002
M1449 Friis [27] blood
10 Linn and Kass [21] vagina
Mycoplasma species Source
M. arginini G230
M. lipophilum MaBy
M. primatum HRC 292
M. pulmonis ASH PB34
M. hyorhinis AMRC 108
M. bovis Donetta PG45
M. buccale 20247
M. fermentans PG18
M. genitalium G37
M. pneumoniae FH
M. salivarium PG20
M. orale CH19299
M. arthritidis PG6
U. urealyticum Serovar 8 (T960)
U. parvum Serovar 6 (Pirillo)
Human Source:
Genomic DNA Hep2; ATCCBMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
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reverse primer I, 5 copies/µl of PG21 were present in every
run, and therefore this primer was chosen for the follow-
ing experiments.
In order to obtain optimal detection in the annealing
phase of the PCR we designed the probes to anneal to the
same strand as the forward primer and placed them as far
as possible from that primer (fig. 1). One hybridization
probe was labelled with fluorescein (FL) in the 3' end, the
other with LightCycler Red705 (LCred705) in the 5' end.
When the probes are hybridized less than 5 nucleotides
apart, Fluorescence Resonance Energy Transfer (FRET)
will be induced. The distance between the two probes was
one nucleotide after annealing to template DNA allowing
FRET light to be measured.
Sensitivity and specificity
Dilution series of the standard DNA from M. hominis
PG21 were used to examine the sensitivity of the LightCy-
cler PCR assay. The fluorescence curves are shown (fig.
2a). Detection of PCR product was possible for the lowest
DNA concentration: 1 copy/µl, equal to 2 copies in the
reaction mixture (fig. 2a). To reduce the noise, the cut-off
value was set to 0.1. The standard curve had an average
slope equal to -3.5, which means that the efficiency of the
PCR reaction was 1.93 (oscillating between 1.9 and 2.0)
(fig. 2b). Calculations of the efficiency derived from the
function for the amount of PCR product that was formed,
represented by equation: N = N0 × 2n, where N is the
number of amplified product, N0 is the initial number of
molecules and n is the number of the PCR cycles. Ideally
the efficiency equals 2. Additionally, the sensitivity of the
assay was determined for two other M. hominis isolates by
making dilution series of DNA from M. hominis 132 and
4712. As for PG21, detection of a PCR product was possi-
ble for the lowest DNA concentration of 1 copy/µl
indicating similar sensitivity of the two other isolates. The
standard curves had slopes equal to -3.552 for isolate 132
and -3.576 for isolate 4712, the efficiency of the PCR reac-
tion was 1.91 and 1.9, respectively.
Table 2: Primers and probes sets used in the study
Oligonucleotide Nucleotide position Sequence
Forward Primer 295–322 5'-GGAAGA-TATGTAACAAAAGAAGGTGCTG-3'
Reverse Primer I 411–438 5'-TTTATCTTCTGGCGTAATGATATCTTCG-3'
Reverse Primer II 430–457 5'- ATGAAGCGCCTGATAAAATTTTATCTTC-3'
Probe I 336–368 5'-AGCAGGTGCTAAAAAGGTGTTTATTACTGCTCC-FL-3'
Probe II 370–408 5'-LCred705-GCTAAAAGCGAAGGTGTTAAAACAGTT GTTTATTCAGTA-3'
Sensitivity of LightCycler PCR in standard dilution series Figure 2
Sensitivity of LightCycler PCR in standard dilution 
series. (a) The LightCycler PCR run with M. hominis PG21 
DNA and fluorescence probes was done. The fluorescence 
signal of 10-fold dilution series from 105 to 5 and 1 copy is 
shown. No reaction was noted in the negative control (0 
copies). (b) Standard curve was generated from the thresh-
old cycles (Ct) also known as crossing points (Cp) of the M. 
hominis PG21 standard dilution series by the LightCycler 
software.
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To determine the reproducibility of the assay, ten dilution
series of PG21 DNA were analyzed in different PCR runs,
and the values of crossing-points (also known as thresh-
old cycles – Ct) were compared by calculation of the coef-
ficients of variation (CV). The values of CV were between
3.8% and 6.7% (table 3). In all runs 10 out of 10 samples
were positive except for 1 copy/µl where a PCR product
was seen in 6 out of 10 PCR runs. The reproducibility of
the assay for the two other M. hominis isolates 132 and
4712 was analyzed in three different PCR runs. In both
isolates dilution of 5 copy/µl was present in three out of
three runs, similarly to PG21 the dilution of 1 copy/µl was
present in two out of three LightCycler runs. Our detec-
tion limit was therefore 5 copy/µl, equals to 10 copies in
the reaction mixture. The reproducibility of the assay was
acceptable.
As a next step twenty M. hominis isolates (table 1) were
tested with the designed primers and probes in the Light-
Cycler real-time PCR. All isolates gave a positive fluores-
cence signal and the concentration of DNA was similar to
104  copies/µl of PG21, measured by the LightCycler
instrument (fig. 3).
The specificity of the LightCycler assay targeting the gap
gene was evaluated by testing human DNA and DNA from
different  Mycoplasma  species. With the specific probes
there was no cross-reactivity to other Mycoplasma species
or human DNA (fig. 4a). For human DNA we used a con-
centration of 104 copies/µl calculated by OD measure-
ments of the purified DNA and the genome size.
Since DNA from different mycoplasmas was extracted by
proteinase K treatment of PBS washed pellets, we tested
such extracted DNA for presence of inhibitors. Two µl of
DNA from five different mycoplasmas (M. arginini, M.
bovis, M. hyorhinis, M. pulmonis, M. salivarium) were spiked
with 2 µl of PG21 DNA of 100 copies/µl and added to the
reaction mix. As illustrated (fig. 4b) there was no inhibi-
tion in the proteinase K treated samples.
Table 3: Reproducibility of the LightCycler-PCR
Copy number No. of PCR runs where 
fluorescence gave positive 
signal
CP SD CV % of CP
105 10 / 10 25.4 1.7 6.7
104 10 / 10 28.7 1.6 5.5
103 10 / 10 32.3 1.6 4.8
102 10 / 10 35.8 1.7 4.8
101 10 / 10 39.7 2.1 5.3
5 copies 10 / 10 40.6 2.3 5.6
1 copy 6 / 10 43.8 1.7 3.8
CP = crossing-points, mean value
CV = coefficient of variation
SD = standard deviation
Statistical analysis of standard dilution series of standard PG21 DNA was performed. Ten different runs were analysed for crossing-points values 
and for presence of fluorescence signal. Based on crossing-points values the standard deviation of single concentration was calculated and 
coefficient of variation as a function: CV% = (SD / Average CP value for each concentration) × 100%.
Specificity of the LightCycler PCR Figure 3
Specificity of the LightCycler PCR. The LightCycler 
PCR run with different M. hominis isolates. Concentration of 
DNA from different isolates used in the study was estimated 
to 104 copies/µl of PG21 DNA, which was used as a standard 
DNA.
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Melting curve analysis
Melting curve analysis can be used to determine the pres-
ence of non-specific amplification products. The melting
temperature (Tm) is defined as the temperature at which
half of a duplex-DNA becomes single-stranded [33]. As it
was impossible to place probes in completely conserved
regions (fig. 5), we analyzed the melting curves of the real-
time PCR products of the different M. hominis isolates. Tm
of PG21 DNA was 66°C and equal for high and low con-
centrations of DNA.
It was shown that the melting temperature of the PCR
products of M. hominis DNA clustered in 3 major groups
(fig. 6). The isolates V2785 and P71 had the same temper-
ature of 66°C as PG21, the second group 93, 7357, 132,
P2, P7, SC4, DC63, 7808, 183, 1893, 10, W2 had a melt-
ing temperature of 64°C, while the last group 5941, 4712,
3105, M1449, 6188, had the melting temperature of
62°C. These different melting points were in agreement
with variation in the DNA sequence of the probe regions
(fig. 5).
Coloured media and possible PCR inhibition
Many Mycoplasma species were cultured in SP-4 or BEa
media for specificity of LightCycler analysis. Additionally,
the clinical samples were transported in SP-4 medium,
which can be used for the recovery of M. hominis [34], and
BEa medium was used for cultivation of M. hominis.
Therefore, to see the effect of the coloured media on the
LightCycler assay, we constructed artificial samples con-
sisting of SP-4 or BEa medium spiked with DNA of known
concentration (105, 104, 103). Two µl of the samples were
analyzed by the LightCycler PCR. As shown (fig. 7), BEa
medium completely inhibited the reaction, whereas SP-4
inhibited only partially, but markedly reduced the PCR
efficiency.
Specificty of the LightCycler PCR Figure 4
Specificty of the LightCycler PCR. (a) LightCycler PCR 
with human DNA from Hep2 cells and selected Mycoplasma 
spp. run with the designed primers and probes. (b) Spiking 
assay showed no inhibition when DNA from five different 
Mycoplasma species (M. arginini, M. bovis, M. hyorhinis, M. pul-
monis, M. salivarium) was spiked with PG21 DNA of 102 cop-
ies/µl. All curves came up at the same time as 102 copies/µl of 
PG21 from the standard dilution series (marked with 
squares).
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Sequence alignment of the probe region of M. hominis isolates Figure 5
Sequence alignment of the probe region of M. hom-
inis isolates. The sequence of PG21 was used as a template. 
The probe sequences from the M. hominis isolates are shown. 
Highlighted base pairs corresponded to differences in probe 
sequences in comparison to PG21 standard. Groups are 
shown in boxes: top box represents the lowest melting tem-
perature of 62°C, group 3, with isolates; 3105, 4712 and 
5941; medium box contains: 7808, DC63, P2, SC4, 132, 7357 
and 93 that have a melting temperature of 64°C; and bottom 
box with V2785 is almost identical to PG21 with only one 
mismatch and a melting temperature of 66°C.
         336                                                  386 
 3105GAP A GCTGGTGCTA AAAAGGTATT TATCACTGCT CCAGCTAAAA GCGAAGGTGT
 4712GAP A GCTGGTGCTA AAAAGGTATT TATCACTGCT CCAGCTAAAA GCGAAGGTGT  3 
 5941GAP A GCTGGTGCTA AAAAGGTATT TATCACTGCT CCAGCTAAAA GCGAAGGCGT
 7808GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2 
 C63-GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2
  P2-GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2
 SC4-GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2 
 132-GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2 
7357-GAP A GCTGGTGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGCGT  2 
  93-GAP A GCAGGCGCTA AAAAGGTATT TATTACTGCT CCCGCTAAAA GCGAAGGCGT  2 
V2785GAP A GCAGGTGCTA AAAAGGTATT TATTACTGCT CCAGCTAAAA GCGAAGGTGT
 PG21GAP A GCAGGTGCTA AAAAGGTGTT TATTACTGCT CCAGCTAAAA GCGAAGGTGT  1 
I PROBE     II PROBE 
           387                                                436 
 3105-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACG CCAGAAGATA
  4712GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACG CCAGAAGATA  3 
  5941GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA
  7808GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
 DC63-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2
   P2-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
  SC4-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
  132-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
 7357-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
   93-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATAATTACA CCAGAAGATA  2 
V2785-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATCATTACG CCAGAAGATA
 PG21-GAP  TAAAACAGTT GTTTATTCAG TAAACGAAGA TATCATTACG CCAGAAGATA  1 BMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
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Analysis of clinical samples
Culture
Eighty-three endocervical samples from women attending
fertility clinics in Denmark were cultured for the presence
of M. hominis. Two samples were found positive. Three
passages were examined for colour change, at each
passage the colour of the medium turned pink, and sam-
ples were thus considered as positive cultures. Proteinase
K treated culture materials were analyzed by Mycoplasma-
genus-specific PCR [35], which gives PCR products from
16S rRNA gene of 265 bp in size. The PCR products from
the two positive clinical samples were sequenced and the
resulting DNA sequence confirmed them to be M. hominis.
Quantification by culture of these two positive samples
was performed by limited dilution in growth medium.
There was a colour change in 9 wells in both samples,
which corresponds to 25.600 CCU/ml in the swab sam-
ple, calculated from titration.
LightCycler PCR on DNeasy treated samples
The cervical swab samples were DNeasy treated and tested
in duplicates by LightCycler PCR using the M. hominis gap-
assay. Two samples (nos. 56 and 83) were positive when
examined by LightCycler PCR (2.4%). The copy numbers
were measured to be 220 (for 83) and 530 (for 56) copies/
µl respectively. The amount of DNA copies per ml in the
original sample was calculated to be 37.000 for sample 83
and 88.500 for sample 56. The two quantification meth-
ods for estimating bacterial load in positive samples thus
showed that the number of live Mycoplasma cells was 69%
(patient 83) and 29% (patient 56) of what was found by
PCR. The positive clinical samples showed melting
temperature of 64°C corresponding to the second group,
in which the majority of the M. hominis isolates were
found. Reproducibility of the quantification of DNA in
the clinical specimens was analyzed in 10 negative patient
samples. Four µl of samples were spiked with 2 µl of PG21
DNA of known concentration (100 copies/µl). The six µl
were added to the LightCycler PCR reaction. No inhibi-
tion was observed (fig. 8).
In some DNeasy treated clinical samples a slight fluores-
cence response was seen at the very late PCR cycle. To ana-
lyze whether this slight fluorescence response was
unspecific, different DNeasy samples were analyzed. We
used different concentrations of human DNA from "Myc-
oplasma free" Hep2 cells, which were purified with Blood
& Cell Culture DNA Mini Kit, and these samples did not
give a positive fluorescence signal when run in LightCycler
PCR (fig. 9a). In addition the results showed that there
was no cross-reaction to human DNA. However, when
DNA free water and standard dilutions of the human
DNA extracted by the Blood & Cell Culture DNA Mini Kit
were treated with DNeasy Tissue Kit, we experienced a
slight fluorescence signal at the very late cycle numbers.
Even DNA free water gave a positive signal (fig. 9a). The
calculated copy numbers were between 1–8 copies/µl. The
melting curve analysis showed an atypical flat and broad
melting curve with the melting peak below the range of
Mycoplasma hominis isolates (fig. 9b).
Clinical samples showing the low concentration (between
1–8 copies/µl) also had the flat melting curve with the
Melting peak analysis with M. hominis isolates Figure 6
Melting peak analysis with M. hominis isolates. Melting 
curve analysis of M. hominis isolates was performed after 
quantification step. The three melting temperatures are 
marked with arrows. Two concentrations of PG21 DNA 
standard dilution series are shown. All samples were run 
with concentration of 104 copies/µl.
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melting peak below 61°C (fig. 9b) and were therefore
considered as negative. One additional sample (no. 9)
had an average concentration of 10 copies/µl, but when
comparing the melting curve data, it had a melting curve
identical to the DNeasy treated water and was therefore
considered negative. There was thus 100% agreement
between cultivation and detection by real-time PCR.
LightCycler PCR on proteinase K treated clinical samples
To additionally confirm that samples which gave a slightly
positive fluorescence signal in LightCycler PCR after
DNeasy treatment were not containing M. hominis DNA,
we analysed proteinase K treated samples from those
patients by the LightCycler PCR. None of the samples gave
a positive fluorescence signal. After confirming that all
samples were negative, we spiked 2 µl of each sample with
2 µl of PG21 DNA of 100 copies/µl, as the control for inhi-
bition. None of the proteinase K treated samples showed
inhibition. This clearly indicates that those samples were
negative.
Discussion
A rapid quantitative real-time PCR for detection of M.
hominis from cervical swab samples was developed. To our
knowledge it is the first LightCycler PCR protocol where
quantification of M. hominis is combined with melting
curve assay. The LightCycler PCR reproducibility was able
to detect down to ten copies/reaction of the genomic
PG21 DNA. All other 20 M. hominis isolates were positive
in the assay. Additionally, isolates 132 and 4712, which
based on melting temperature belong to the two other
groups than PG21, were used to document detection lim-
its of M. hominis isolates. Similarly to PG21, the detection
limits were 5 copies/µl, equals to 10 copies per reaction
for both isolates.
The average efficiency was high, but small differences were
seen. This can be caused by different factors such as
presence of inhibitors in the sample and treatment of the
sample.
The artificially constructed samples consisting of PG21
DNA and coloured BEa and SP-4 media showed that these
media inhibited the PCR reaction indicating that it was
crucial to wash the pellets of other Mycoplasma species
with PBS. Additionally, a spiking assay where DNA from
other mycoplasmas was used together with DNA from
PG21 showed that there was no inhibition in the protein-
ase K treated samples.
Since swab samples may contain PCR inhibitors we intro-
duced the DNeasy procedure to additionally purify DNA
from proteinase K treated clinical samples. Analysis of the
ten negative clinical samples spiked with DNA from PG21
(100 copies/µl) showed no inhibition after DNeasy
treatment.
We experienced, however, some slight fluorescence
response in the very late cycle number, which corresponds
to the low concentration seen in DNeasy treated water or
Hep2 cells (fig. 9a) and flat melting curves with lower
melting temperature than those of M. hominis isolates (fig.
9b). DNeasy treated patient samples that gave such a weak
fluorescence signal were considered as negative. Addition-
ally, using the original proteinase K treated patient sam-
ples, for those patients that gave a weak fluorescence
signal after DNeasy treatment, we did not see any reaction
with LightCycler PCR. This strongly indicates that such
slight fluorescence response is generated only in the
DNeasy treated samples.
A previous study showed that women with bacterial vagi-
nosis showed presence of M. hominis in 38.5% compared
to 8.3% of women with normal microbial flora [36]. Since
none of our patients had bacterial vaginosis we had
expected approximately 8% of our samples to be positive.
We found two positive samples that were confirmed to be
positive by the culture and had a high concentration of
DNA by LightCycler PCR (220 and 530 copies/µl). The
low number of positive patients (2.4%) was surprising
but comparable with a previous study made on patients
undergoing the in-vitro fertilization [7].
Comparison of the number of DNA copies and CCU
showed that the CCU was lower than the number of DNA
Reproducibility of the LightCycler assay in clinical samples Figure 8
Reproducibility of the LightCycler assay in clinical 
samples. The LightCycler PCR run of 10 negative clinical 
samples spiked with the known PG21 DNA concentration of 
102 copies/µl. The assay showed no inhibition, all curves 
came up at the same time as 102 copies/µl of PG21 (marked 
with squares) from the standard dilution series.
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 5 10 15 20 25 30 35 40 45 50
Cycle No.
F
l
u
o
r
e
s
c
e
n
c
e
 
F
3
/
F
1
10
5 c/µl
10
4  c/µl
10
3 c/µl
10c/ µl 1 c/µl
5 c/µl
10 negative 
patient 
samples 
spiked with 
10
2c/µl of 
PG21BMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
Page 9 of 13
(page number not for citation purposes)
copies. This can be explained by the presence of dead bac-
teria in the samples.
Even though the assay was designed for quantification,
the variability in the melting peaks gave additional
information of M. hominis. Differences in the melting
temperatures between M. hominis isolates prove heteroge-
neity of the housekeeping gene sequence. The Tm value
determines how well the sequence of probes matches the
sequence of template DNA, and it will decrease if
mismatched DNA is amplified. Single mismatch can
decrease the Tm from 1°C up to 30°C [37,38] depending
on many factors, such as pH, duplex length and G + C
content. This kind of analysis is used in detection of sub-
types of Herpes simplex virus, since the Tm discriminates
between two different subtypes [33,39,40]. In the present
study, Tm of the clinical samples can suggest to which
group of isolates they belong and how different they are
from the PG21 template DNA. In this study, patient sam-
ples nos. 56 and 83 had melting peaks similar to isolates
from the second and largest group.
DNeasy treated samples Figure 9
DNeasy treated samples. (a) Two LightCycler PCR runs, first one with standard dilution series of human Hep2 DNA 
before (flat negative curves) and after DNeasy (indicated with squares and triangles), showed on the left and second with DNA 
free water before (marked with squares) and after DNeasy (triangles) on the right. (b) Melting curve analysis of DNeasy 
treated H2O (triangles), Hep2 DNA (squares) and clinical sample.
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The real-time technology where measurement of the fluo-
rescence emitted during amplicon production is
performed during each PCR cycle is considered as a break-
through in PCR. Conventional PCR is an open,
contamination-susceptible system where it is necessary to
transfer the amplified product to other detection systems
to confirm a positive result. Real-time PCR benefits by a
closed system in which formation of a product is meas-
ured immediately without transfer [32]. Interpretation of
LightCycler PCR results, presented as graphs and calcula-
tion of crossing points, introduces many advantages, but
such a parameter of real-time PCR should be evaluated.
Conclusions
LightCycler PCR appears very promising for detection of
organisms that are difficult to culture or whose growth is
slow. We have developed a quantitative, specific LightCy-
cler protocol for detection of M. hominis, which offers
rapid diagnosis of one hour after DNA extraction. The
DNA extraction method used was not the best choice as
unspecific fluorescence did occur in the late number of
cycles. Results from cultivation and LightCycler PCR were
identical. The method is both sensitive and specific. All
tested isolates gave a positive fluorescence response, and
final amplification and quantification was performed in
closed tubes, which reduces the risk of contamination.
The described target gap gene sequence should be pre-
ferred to more varying parts. A small variation in this part
of the gap gene among different M. hominis isolates was
observed by the melting curve analysis.
Methods
Microorganisms and human DNA used for the study
Organisms used in this study are listed in table 1.
Subjects
A total of 83 consecutive women attending fertility clinics
in Denmark (Brædstrup/Horsens and Holstebro) were
studied. All patients were undergoing hysteroscopy and
transvaginal hydrolaparoscopy (culdoscopy) [41] or
laparoscopy due to infertility. The endocervical specimens
for detection of presence of M. hominis were collected
before the scopic examination.
Material collection
Endocervical specimens were obtained using a sterile
chlamydial swab and the contents transferred immedi-
ately into a tube containing 2 ml of transport medium, SP-
4 [42], containing thallium acetate (0.01%), which inhib-
its growth of other microorganisms. Such prepared sam-
ples were then sent to the laboratory of Department of
Medical Microbiology and Immunology, Aarhus Univer-
sity, where they were stored at -70°C.
Cultivation and harvesting of microorganisms and human 
Hep2 cells used in the study
All isolates of M. hominis, M. buccale, M. salivarium, M.
orale, M. arthritidis, M. arginini, M. lipophilum, M. primatum
were cultivated in 1.7 ml of broth BEa medium [22]. U.
urealyticum and U. parvum were grown in 1.7 ml of SU
medium [43]. M. pneumoniae and  M. genitalium were
grown in 100 ml of SP-4 medium [42] as described in
detail elsewhere [44]. M. fermentans, M. pulmonis, M.
hyorhinis were cultivated in 1.7 ml of BEg medium [43].
Finally, M. bovis was cultured in BE medium [43]. All cul-
tures were incubated at 37°C. The BEa medium changed
colour from orange to pink in 48 hours due to reduction
of phenol red by arginine hydrolysis. SP-4 and BEg both
changed colour from orange to yellow, whereas SU
changed from yellow to orange. BE medium changed
from yellow to light pink in 72 hours. Except for M.
hominis, M. genitalium and M. pneumoniae, which were
cultivated up to bigger volumes (100 ml), 500 µl of the
colour changed cultures were then placed in 7 ml of the
new medium, and harvested after the medium changed
for the second time. One ml of logarithmic-phase culture
was centrifuged in Eppendorf tubes at 20.000 × g for 30
min. Each pellet was washed twice by phosphate-buffered
saline (PBS) and the pellets were stored at -70° prior to
use.
Human Hep2 cells were cultured as described elsewhere
[45].
DNA extraction and purification from microorganisms and 
human Hep2 cells used in the study
DNA from M. arginini, M. bovis, M. hyorhinis, M. pulmonis,
M. primatum, M. lipophilum, M. buccale, M. salivarium, M.
orale, M. arthritidis, U. urealyticum, U. parvum, M. pneumo-
niae  and  M. fermentans was extracted by suspending
pellets in 160 µl TE buffer, and adding 40 µl 10 mg/ml
proteinase K. The proteins were digested by incubation at
55°C for one hour, followed by inactivation of the
enzyme by boiling for 10 minutes at 100°C.
The DNA from human Hep2 cells as well as M. genitalium
DNA was extracted and purified by Blood & Cell Culture
DNA Mini Kit (QIAGEN GmbH, Hilden, Germany).
Genomic DNA from all M. hominis isolates was extracted
as described [46] and followed by ultracentrifugation in
CsCl-ethidium bromide density gradient [47].
Concentrations of DNA from isolates PG21, 132 and
4712, and human Hep2 DNA were calculated after meas-
uring OD (optical density) at 260 and 280 nm with
Unicam 8625 UV/VIS spectrometer (ATI Unicam, Cam-
bridge, United Kingdom).BMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
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Artificial "Mycoplasma free" samples treated with DNeasy 
Purification Kit
Fourfold dilution series of human Hep2 DNA purified by
Blood & Cell Culture DNA Mini Kit (QIAGEN GmbH,
Hilden, Germany) of initial concentration 8.000 copies/
µl were prepared. Twenty-five µl of each dilution and
DNA free double distilled water were then treated with
DNeasy™ Tissue Kit (QIAGEN GmbH, Hilden, Germany)
procedure. Samples were diluted twice, because of elution
step with 50 µl of elute buffer, and therefore 4 µl instead
of two of each sample were used in the LightCycler PCR
run.
Cultivation of patient cervical samples
Broth BEa medium was used for culture of M. hominis. To
avoid overgrowth by other bacteria, present in the uro-
genital tract, a special mixture of antibiotics (Niels Friis;
containing: 0.15 mg/ml cycloserine, 0.2 mg/ml
vancomycin, 0.2 mg/ml bacitracin and 0.2 mg/ml mecil-
linam) was used. Twenty µl of the swab sample was placed
in 1 ml of medium with Niels Friis antibiotics and incu-
bated at 37°C. The BEa medium changed colour from
orange to strawberry pink in 48 hours due to reduction of
phenol red by arginine hydrolysis. Finally, samples were
described as positive when it was possible to pass them
further 2 times. Mycoplasma-genus-specific PCR was
performed on the two positive cultures and the PCR prod-
ucts were sequenced. Sequencing reactions were carried
out bidirectionally using the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin Elmer,
Narwalk, USA) on the purified PCR products according to
the instructions supplied by the manufacturer. Sequenc-
ing was performed on an ABI PRISM 377 DNA Sequencer
(Perkin Elmer, Narwalk, USA).
DNA extraction from cervical samples
All 83 patient samples were treated identically. Briefly,
three hundred µl of the original swab sample was sub-
jected to microcentrifugation at 20.000 × g, and to remove
transportation medium the pellets were washed twice
with PBS. The pellets were suspended in 49 µl TE buffer,
and 1 µl 10 mg/ml Proteinase K was added, proteins were
digested while incubating at 55°C for one hour, which
was followed by inactivation of the enzyme by boiling for
10 minutes at 100°C. Finally, in order to remove possible
inhibitors present in swab samples, DNA extraction with
DNeasy™ Tissue Kit (QIAGEN GmbH, Hilden, Germany)
was performed on the resulting solution without repeat-
ing the proteinase K treatment. Twenty-five µl of the pro-
teinase K treated sample was diluted twice because of
elution with 50 µl of elute buffer, 4 µl of each sample was
used for the PCR. The filter pipette tips were used for all
DNA preparation steps to reduce possibility of sample
contamination.
Quantification of the number of viable microorganisms by 
culture
Estimation of the number of M. hominis in patient swab
samples was performed by titration in BEa growth
medium. Two-fold dilutions were made in ELISA trays by
adding 0.01 ml of the clinical sample to 0.19 ml of BEa
medium. The plates were incubated at 37°C and reading
was performed on the third day. Plates were left in
incubator and observed for 3 additional days but no fur-
ther change appeared. The last well with visible colour
change was considered to contain one colour changing
unit (CCU) allowing us to calculate the number of viable
microorganisms in the original clinical sample.
Primer and probe design
Primers and probes were designed from the gap gene of
Mycoplasma hominis type strain PG21 (Accession No.
AJ243692). This gene belongs to the housekeeping genes
and is therefore very conservative in all organisms. Primer
and probe sequences and their locations are present in
table 2. Both primers and probes were placed in front of
the conserved region of the gap  gene that is almost
identical in all organisms. Primers were obtained from
DNA Technology, Aarhus, Denmark, and probes from
TIB-MOLBIOL, Berlin, Germany. Probe and primer
sequences were analysed by BIOBASE (The Danish Bio-
technological Database, the University of Aarhus, Den-
mark) and BLAST (National Centre of Biotechnology
Information, National Institutes of Health, Bethesda, MD,
USA).
Real-time PCR assay with hybridization probes
The PCR product was 144 bp in size, which according to
the manual (Roche Molecular Biochemicals Technical
Note No. LC 11/2000) is preferable to perform an effi-
cient quantification of DNA.
Real-time PCR was performed in glass capillary tubes. The
reaction mixture was composed of 0.5 µM of each primer,
0.2 µM of each probe, 5 mM of MgCl2 (PCR buffer), 2 µl
of ready-to-use Fast Start DNA Master Hybridization
Probes (Roche Diagnostics, Mannheim, Germany)
(contains a hotstart Taq DNA polymerase and reaction
mixture), 1.5 µl Uracil-DNA Glycosylase (heat-labile) and
2 µl of the DNA template. Water was added up to 20 µl,
which was the final volume of all reaction-mix. For the
DNeasy treated patient samples 4 µl of DNA was used.
When proteinase K treated patient samples were exam-
ined (without DNeasy treatment), we used 2 µl of the
undiluted DNA.
To avoid contamination, mixing of the reagents (except of
the DNA template) was performed in a separate room,
away from rooms where culturing and DNA purification
were done. The DNA template from M. hominis PG21 wasBMC Microbiology 2004, 4:35 http://www.biomedcentral.com/1471-2180/4/35
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added by use of filter pipette tips. Uracil-DNA Glycosylase
(Roche Diagnostics, Mannheim, Germany) was used to
prevent the samples from possible PCR "carry-over" con-
taminations from previous DNA synthesis reactions.
Reaction mixes contained dUTPs instead of dTTPs, and
therefore it was possible to avoid contamination of
samples by adding an enzyme that hydrolyzes uracil-gly-
cosidic bonds at U-DNA in single and double-strained
DNA [48].
As negative control a sample containing all reagents
except DNA was used in every PCR run. Quantification of
DNA concentrations performed by LC-PCR Software was
based on standard dilution series with known
concentrations of genomic M. hominis PG21 DNA. The
concentrations of standard dilution series were: 105, 104,
103, 102, 101, 5 and 1 copy/µl. Siliconized tubes were used
to prevent DNA from sticking to the wall of the plastic
tubes. For carrier, yeast RNA was used in concentration 10
µg/ml.
The LightCycler PCR program was composed by: Hotstart
Taq DNA polymerase activation done in 95°C for 10 min-
utes, followed by cycling: 95°C (20°C/s) for 15 s, 58°C
(20°C/s) for 8 s and 72°C (20°C/s) for 8 s, repeated 45
times. Melting assay ended the analysis: samples were
heated to 95°C (20°C/s) without hold, cooled to 55°C
(20°C/s) hold for 15 s and then heated slowly at 0.1°C/s
up to 95°C, finally cooled to 40°C (20°C/s).
Fluorescence emitted at 705 nm was measured at each
annealing step since the fluorescence signal is emitted
when both probes are hybridized. After annealing the
temperature is raised and the hybridization probes are dis-
placed by the Taq polymerase during the elongation step.
Probe fluorescence was detected in canal F3 (measures at
705 nm) and F1 (measures at 530 nm). F3/F1 was used to
correct differences in volume of the samples made during
pipetting.
Quantification of LightCycler products
The results were interpreted with LightCycler software
Vers. 3.5 (Roche Diagnostics). Quantification software
performs all additional steps for generation of a standard
curve. First step involves Baseline Adjustment with the use
of a "fit points" method, second step allows background
reduction using Noise Band correction, and the last step is
Analysis where the standard curve is generated from the
threshold cycles (Ct) of the standard dilution series (fig.
1b). Samples with high DNA load had low Ct values, and
low DNA load had high Ct values. The concentration of
DNA in clinical samples was set as "unknown". Each sam-
ple was run in duplicate. Calculation of the DNA concen-
tration in the unknown sample was based on the standard
curve slope. The average of the two concentration meas-
urements was used for further analysis.
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